In this Bio-Rad Transfusion Science Webinar, Dr. Carla Dinardo presents studies linking IgG1 and IgG3 subclasses with hemolysis risk in red blood cell allo- and autoantibody contexts, comparing their frequency and in vitro behavior with other IgG subclasses in patients and blood donors with RBC autoantibodies.
Webinar Learning Objectives:
- Explore the role of IgG antibodies, particularly subclasses IgG1 and IgG3, in driving hemolysis via Fc receptor engagement and complement activation
- Discuss study results on the correlation between IgG1 and IgG3 subclasses and hemolysis risk in RBC allo- and autoantibody contexts
- Discover in vitro behavior of IgG1/IgG3 versus other IgG subclasses in patients and blood donors with RBC autoantibodies.
About this Webinar
Immune-mediated hemolysis occurs when allo- or autoantibodies target RBC antigens, causing increased RBC destruction or reduced lifespan. This underlies conditions like Autoimmune Hemolytic Anemia (AIHA), Hemolytic Disease of the Fetus and Newborn (HDFN), and Hemolytic Transfusion Reactions (HTR). IgG antibodies, particularly subclasses IgG1 and IgG3, drive hemolysis via Fc receptor engagement and complement activation. Simple lab tools assessing IgG levels and subclasses on RBCs can help predict hemolysis risk in AIHA, incompatible transfusions, and HDFN.
Register NowTuesday
8 AM PST, 5 PM CET
About the presenter:
Carla Donado, MD, PhD
Dr. Carla Donado is a hematology researcher specializing in immune-mediated hemolysis. She earned her MD and PhD from the University of São Paulo and has published extensively on hemolytic disorders.